PT  - JOURNAL ARTICLE
AU  - Jalkanen, Juho
AU  - Khan, Sofia
AU  - Elima, Kati
AU  - Huttunen, Teppo
AU  - Wang, Ning
AU  - Hollmén, Maija
AU  - Elo, Laura L.
AU  - Jalkanen, Sirpa
TI  - Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19
AID  - 10.1101/2022.03.10.22272123
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.10.22272123
4099  - http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272123.short
4100  - http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272123.full
AB  - The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). Here we report a novel disease association of a SNP rs9984273, which is situated in the interferon alpha/beta receptor (IFNAR2) gene in an area corresponding to a binding motif of the glucocorticoid receptor (GR). The minor allele of SNP rs9984273 associates with higher IFNAR expression, lower IFN-gamma and IL-6 levels and less severe form of coronavirus diseases (COVID-19) according to the COVID-19 Host Genetics Initiative database, and better outcome in interferon (IFN) beta treated patients with ARDS. Thus, the distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signalling and glucocorticoids.One-Sentence Summary Single nucleotide polymorphism in interferon receptor contributes to corticosteroid response and outcome in ARDS and COVID-19Competing Interest StatementJJ is an employee of Faron Pharmaceuticals, JJ, MH and SJ own stocks of Faron PharmaceuticalsFunding StatementThis study was supported by the EU FP7 program, Traumakine, the Finnish Academy, the Jane and Aatos Erkko Foundation and the Sigrid Juselius FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics connected to the clinical trials (NCT00789685 and NCT02622724) has been thoroughly presented in references 18 and 20 (Bellingan et al, Lancet Respiratory Medicine 2014 and Ranieri et al, JAMA 2020). The lung specimens were obtained under permission of the ethics authorities of Turku University Hospital (Finland).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.